TNFRSF4 and neoplasm: The CpG+OX40 combination is improving the immune effector to Treg ratios in the TME and is favorably changing the gene expression of the TME, but the in situ vaccine is not consistently causing an anti-tumor response in the B78 or 4T1 models.